M Global Insight August 26, 2025 10:24 PM GMT Global Biopharma China Biotech: Innovation Dawn The global biotech sector is at a pivotal moment as China transitions from traditional generics manufacturing into the global innovation ecosystem. By 2040, we project China-originated assets to represent 35% of US FDA approvals. We see significant implications for the global biopharma industry. Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors sh ...

Core Insights - ArriVent BioPharma, Inc. has appointed Dr. Merdad Parsey to its Board of Directors, bringing extensive experience in global clinical development from his previous role at Gilead Sciences, Inc. [1][2] - Dr. Parsey expressed enthusiasm about ArriVent's potential to transform cancer treatment with its lead candidate firmonertinib and its pipeline of next-generation antibody drug conjugates (ADCs) [2][3] - ArriVent is focused on developing differentiated medicines to meet unmet medical needs in cancer treatment, leveraging its team's drug development expertise [3] Company Overview - ArriVent is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of innovative therapeutics for cancer patients [3] - The company aims to maximize the potential of its lead candidate firmonertinib and advance its ADC pipeline through approval and commercialization [3] Leadership Experience - Dr. Parsey has held significant roles in the biopharmaceutical industry, including Senior Vice President at Genentech and CEO of 3-V Biosciences, Inc. [2] - His academic background includes an M.D. and Ph.D. in immunology, with training at prestigious institutions such as Stanford University and the University of Colorado [2]